CA
NZ
UK
AU
IND
US
● Analysts had expected about $283 million.
● Revenue of $890.4 million was roughly in line with the $892.5 million expected.
● The stock appears to have moved with quantum and tech names.
● Tuesday's reaction and season outlook are the next focus.
● It cut its 2026 adjusted EBITDA outlook to more than $40 million.
● Acute care revenue climbed strongly to $15.1 million.
● Hold means the analyst no longer expects outperformance.
● That was up about half from a year earlier.
● The extended-trading drop was steep.
● About three in four patients on placebo responded.
Please wait processing your request...